EML4-ALK fusion gene in lung cancer and its biological function

Chinese Journal of Lung Cancer

Volumn 15, Issue 2, 2012, Pages 112-116

  Yang, Tong ^a   Liu, Hongyu ^a   Chen, Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 GENE; FUSION GENE; GENE; GENE FUNCTION; LUNG CANCER;

EID: 84922685652     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.02.09     Document Type: Article

References (26)

1. Souquet PJ, Chauvin F, Boissel JP, et al. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable nonsmall cell lung cancer. Lung Cancer, 1995, 12 Suppl 1: 147-154.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall- cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol, 2003, 21(12): 2237-2246.
5. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30(1 Suppl 1): 30-38.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
7. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
8. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res, 2008, 68(13): 4971-4976.
9. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res, 2008, 14(20): 6618-6624.
10. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol, 2009, 27(26): 4232-4235.
11. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALKpositive lung adenocarcinoma. J Clin Pathol, 2010, 63(12): 1066-1070.
12. Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther, 2009, 8(10): 2811-2820.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26): 4247-4253.
14. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res, 2009, 7(9): 1466-1476.
15. Anastasov N, Bonzheim I, Rudelius M, et al. C/EBPbeta expression in ALKpositive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica, 2010, 95(5): 760-767.
16. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res, 2009, 69(6): 2550-2558.
17. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia, 2008, 10(3): 298-302.
18. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010, 9: 188.
19. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res, 2009, 15(9): 3143-3149.
20. Fukuyoshi Y, Inoue H, Kita Y, et al. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer, 2008, 98(9): 1536-1539.
21. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, 2008, 14(13): 4275-4283.
22. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol, 2009, 22(4): 508-515.
23. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol, 2009, 174(2): 661-670.
24. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol, 2010, 17(3): 889-897.
25. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8): 1723-1733.
26. Brambilla E. Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. Eur Respir J, 2010, 35(4): 717-720.